LGALS9 and myalgic encephalomeyelitis/chronic fatigue syndrome: Gal-9 has been linked to increased organ involvement and mortality in both lcSSc and dcSSc patients (16, 17), rapidly progressive ILD in dermatomyositis patients (18), and has been proposed as a biomarker in patients with PACS complicated by ME/CFS (5).